問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

柯博升

Recruiting

List

109Cases

2024-02-01 - 2038-01-31

Phase III

A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) Compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2)

  • Condition/Disease

    Follicular Lymphoma (FL)

  • Test Drug

    EpcoritamabLenalidomideObinutuzumab RituximabCyclophosphamideDoxorubicinVincristineVincristinePrednisoneBendamustine

Participate Sites
4Sites

Recruiting4Sites

2021-08-01 - 2023-03-28

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2019-12-01 - 2025-06-16

Phase III

Randomized, Open-label, 2-Arm, Multicenter, Phase 3 Study of Venetoclax and Azacitidine Versus Best Supportive Care as Maintenance Therapy for Patients With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy (VIALE-M)

  • Condition/Disease

    Acute Myeloid Leukemia (AML)

  • Test Drug

    Venetoclax Venetoclax

Participate Sites
4Sites

Recruiting4Sites

2020-11-01 - 2026-12-31

Phase III

Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Subjects ≤65 Years With Previously Untreated Non-Germinal Center DLBCL

  • Condition/Disease

    non-germinal center diffuse large B-cell lymphoma

  • Test Drug

    ACP-196

Participate Sites
7Sites

Recruiting7Sites

2023-02-01 - 2025-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2018-09-01 - 2026-10-02

Phase III

A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF LUSPATERCEPT (ACE-536) VERSUS EPOETIN ALFA FOR THE TREATMENT OF ANEMIA DUE TO IPSS-R VERY LOW, LOW OR INTERMEDIATE RISK MYELODYSPLASTIC SYNDROMES (MDS) IN ESA NAiVE SUBJECTS WHO REQUIRE RED BLOOD CELL TRANSFUSIONS

  • Condition/Disease

    Myelodysplastic Syndromes

  • Test Drug

    Luspatercept; Epoetin alfa

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting4Sites

2017-07-18 - 2024-06-30

Phase III

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects 18 Years of Age with previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation

  • Condition/Disease

    Acute Myeloid Leukemia with an IDH1 Mutation

  • Test Drug

    Ivosidenib (AG-120);Azacitidine

Participate Sites
8Sites

Recruiting6Sites

蕭惠樺
Kaohsiung Municipal Gangshan Hospital

未分科

2021-09-01 - 2025-08-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2021-01-01 - 2023-12-31

Phase I

A Phase 1 Study of Oral LY3410738 in Patients with Advanced Hematologic Malignancies with IDH1 or IDH2 Mutations

  • Condition/Disease

    Advanced Hematologic Malignancies with IDH1 or IDH2 Mutations

  • Test Drug

    LY3410738

Participate Sites
2Sites

Recruiting1Sites

Terminated1Sites

2023-01-23 - 2027-10-13

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

1 7 8 9 10 11
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB